#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?

SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.
Source: Modern Treatment of Diabetes 19. 2. 2020

News CASE STUDY: Rocker who can enjoy life again thanks to DM2 compensation p.o. semaglutide and better lifestyle

Diabetologist MUDr. Lucie Radovnická from Masaryk Hospital in Ústí nad Labem illustrates the case of her patient − a sympathetic rocker who enjoys life including concerts, beer, and good food − demonstrating how modern antidiabetic treatment with oral semaglutide in combination with thorough lifestyle re-education can achieve very good diabetes compensation and overall health improvement. One of the many benefits of this modality was the possibility to discontinue sulfonylurea derivative medication, which previously caused severe hypoglycemia.
Source: Modern Treatment of Diabetes with GLP-1 Analogues 18. 6. 2024

News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia

One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.
Source: Chronic Lymphocytic Leukemia 10. 8. 2021

News How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?

Doctors often address the question of how to dose thromboprophylaxis in overweight individuals. The goal is to ensure effective protection against thrombotic complications in stressful situations, such as hospitalization or surgical procedures, without increasing the risk of bleeding.
Source: Thromboprophylaxis 18. 2. 2020

News Physiological and Clinical Effect of Romiplostim in the Treatment of ITP

Romiplostim in the treatment of immune thrombocytopenia (ITP) has demonstrated safety and the promise of long-term remission, enabling many pediatric and adult patients to discontinue treatment and maintain a drug-free state.
Source: Immune Thrombocytopenia 11. 10. 2021

News Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival − Case Report

A recently published case study by Romanian authors presents a rare instance of long-term survival (15 years) in a patient with locoregional prostate cancer that later metastasized. The case illustrates the possibilities offered by currently available modern treatment modalities.
Source: Oncological Treatment 26. 10. 2023

News The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor

Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G protein. The authors of the presented study found that the anti-inflammatory and renoprotective effect of candesartan persists even when the receptor is completely blocked. The aim of the further study was to clarify this mechanism - independent of AT1R.
Source: Sartans in the Treatment of Hypertension 12. 8. 2021

News Could candesartan counteract adverse intestinal changes induced by hypertension?

An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the composition of the microflora. It expands the knowledge of recently described pathophysiological changes in the gut associated with hypertension.
Source: Sartans in the Treatment of Hypertension 6. 3. 2020

News Interactive Case Study of a Patient with Severe Hemophilia A - Experience from Slovenia

Assoc. Prof. Dr. Irena Preložnik Zupan (University Medical Centre Ljubljana) describes an interactive case study of a patient with severe hemophilia A and progressive cataracts in both eyes.
Source: Quality Life Even with Hemophilia 24. 3. 2021

News Lung screening in the Czech Republic has detected over a hundred cases of lung cancer

The purpose of lung screening, which has been ongoing in the Czech Republic since January 2022, is to detect early stages of lung cancer and increase awareness of this malignant disease in relation to smoking. Data analysis from health insurance companies through the National Registry of Paid Health Services (NRHZS) revealed that out of nearly 4,000 individuals who underwent low-dose CT as part of the screening examination, 116 were diagnosed with cancer.
Source: Respiratory Health 7. 12. 2023

News Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint bleeding are also being investigated, though their routine use is not anticipated in the near future.
Source: Hemophilia 10. 6. 2024

News INFOGRAPHIC: How does liposomal ozonized oil work in treating eye infections?

Ozonized sunflower oil exhibits antimicrobial, anti-inflammatory, and healing properties, which is why it is added to eye drops intended for infection prevention. We bring you a clear schematic of the mechanism of action of liposomal ozonized oil.
Source: Treatment of Glaucoma 24. 3. 2023

News Romiplostim brings benefit also to patients with ITP lasting less than 1 year

What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?
Source: Immune Thrombocytopenia 21. 11. 2023

News Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results

The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.
Source: Psoriasis 6. 5. 2022

News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome – Results of a Network Meta-Analysis

A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.
Source: Irritable Bowel Syndrome 12. 10. 2022

News Patient with generalized malignant melanoma treated with nivolumab in the first line

A 75-year-old patient was referred for examination at the dermato-oncology clinic of the Dermatology Clinic of VFN in September 2016. He was being treated for ICHS and had undergone prostate surgery for hyperplasia in 2013.
Source: Case Studies from Immunooncology 10. 9. 2020

News Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?

The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart failure with reduced ejection fraction. About 30–50% of heart failure patients have type 2 diabetes mellitus (DM2). The subject of a post hoc analysis of the PROVE-HF study was to find out whether this benefit of sacubitril/valsartan can be expected in patients with DM2 as well.
Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Benefits and Cost-Effectiveness of Superabsorbent Dressings in the Treatment of Venous Leg Ulcers

A recent cost-effectiveness analysis based on German data showed that using superabsorbent dressings instead of conventional dressings in the treatment of venous leg ulcers with moderate to high exudation increases the likelihood of healing, quality of life, and reduces direct healthcare costs. Similar results were found in another analysis from last year, this time using French data, comparing superabsorbent dressings with foam dressings, again in the treatment of venous leg ulcers.
Source: Wound Healing 26. 4. 2023

News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?

How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.
Source: Hemophilia 27. 11. 2023

News The Presence of COPD Worsens the Course of COVID-19 – Results of Epidemiological Studies

Among the at-risk populations during the current COVID-19 pandemic are older individuals and those suffering from chronic comorbidities. The presence of chronic obstructive pulmonary disease (COPD), according to available data, represents a negative prognostic factor increasing the risk of severe course and mortality.
Source: Treatment of Asthma and COPD 8. 4. 2020

News Von Willebrand Disease as a Cause of Abnormal Uterine Bleeding

Abnormal uterine bleeding constitutes a large portion of complaints among women of reproductive age. This type of bleeding is typical for von Willebrand disease (vWD), but also for other types of coagulation disorders. So, is vWD more frequent in women with abnormal uterine bleeding than in the general population?
Source: Von Willebrand Disease 16. 7. 2021

News Myths Accompanying Therapy of Arterial Hypertension

Arterial hypertension is among the most common yet most underestimated diseases in the adult population. Misinterpretation of data and inadequate management of this disease can be caused, among other things, by an excessive amount of available clinical data and its incorrect analysis. Insufficient control of blood pressure (BP) is, however, one of the most significant factors in increased cardiovascular (CV) mortality.
Source: ACE inhibitory 18. 4. 2021

News Teriflunomide and Pregnancy Planning

The authors of the article published last year in Multiple Sclerosis Journal present data regarding experiences with the use of teriflunomide during pregnancy.
Source: Multiple Sclerosis 25. 3. 2021

News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
Source: Heart Failure 27. 4. 2022

1 22 23 24 25 26 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#